UNSPSC 51111820: Letrozole

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H11N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LKK855W8I, chemically known as 4,4-(1h-1,2,4-triazol-1-ylmethylene)dibenzonitrile but generally known as letrozole, which bears US NIH Compound Identifier 3902. European Medicines Agency schedules Letrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08444MIG.

UNSPSC 51111820 Letrozole, a Commodity code, addresses pharmaceutical procurement by state and local health agencies, though recent activity in this code shows limited direct solicitation for the drug itself. State and local governments procure letrozole—a hormone therapy used in breast cancer treatment—primarily through pharmacy benefit manager contracts, group purchasing organization agreements, and state health plan formularies rather than through independent direct-to-manufacturer or standalone drug solicitations. When state agencies do solicit pharmaceutical supply and pricing, they typically embed drug procurement within broader pharmacy benefit or therapeutic pharmacy initiative RFPs that address multiple medications and delivery channels. The Texas Health and Human Services Commission represents the primary recent issuing body visible under this code tier, signaling that state-level health authorities and Medicaid agencies drive pharmaceutical procurement activity.

The Texas HHS Commission posted a Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities for direct-to-manufacturer pharmaceutical delivery through its Therapeutic Pharmacy Initiative. The RFI solicits information about vendors' experience with direct contracting for self-insured employers and health plans, flexibility to negotiate net pricing models without rebates, and ability to implement value-based agreements—signaling that Texas is exploring alternative supply chains outside traditional pharmacy benefit managers and group purchasing organizations. The RFI does not commit to a specific contract value or award timeline, functioning as exploratory market intelligence to inform a future formal RFP. No other recent state or local opportunities targeting letrozole or related hormone therapies appear in the source, suggesting limited standalone procurement under this Commodity code at present. Activity is concentrated in state health agency procurement offices rather than counties, municipalities, or school districts.